Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.65, No.5, p.673-682, 2018 |
||
Title: MiR-500a-3p inhibits cell proliferation and invasion by targeting lymphocyte antigen 6 complex locus K (LY6K) in human non-small cell lung cancer | ||
Author: X.H. LIAO, Z. XIE, C.N. GUAN | ||
Abstract: LY6K (lymphocyte antigen 6 complex locus K) is an anti-gene in non-small cell lung cancer (NSCLC) and miR-500a-3p promotes the progression of cancers. Evidence shows that increased miR-500a-3p caused LY6K suppression. Herein, we hypothesize that miR-500a-3p takes part in the progression of NSCLC through targeting LY6K. miR-500a-3p expression levels in NSCLC specimens and cell lines were detected by quantitative real-time PCR (qRT-PCR). The mRNA and protein expression levels of LY6K in NSCLC specimens and cell lines were examined by qRT-PCR, immunohistochemistry and western blotting. Dual-luciferase reporter assay assessed miR-500a-3p binding to the LY6K gene. The functions of miR-500a-3p and LY6K in proliferation/invasion and lung metastasis formation were assessed by CCK8, Transwell assay and subcutaneous tumor model in nude mice, respectively. Statistical analysis explored the clinical correlation between miR-500a-3p/LY6K expression and clinical-pathological features. While miR-500a-3p was substantially decreased in NSCLC tissues and cell lines. LY6K protein and mRNA level expressions were increased in NSCLC patients. Clinical analysis indicated that miR-500a-3p and LY6K were related to tumor differentiation, lymph node metastasis and TNM staging in NSCLC patients. MiR-500a-3p suppresses cell proliferation, invasion and metastasis formation in vivo by targeting the LY6K.miR-500a-3p acts as a tumor suppressor in NSCLC partly by down-regulating LY6K expression, and this suggests it is a potential therapeutic target for NSCLC intervention. |
||
Keywords: LY6K; miR-500a-3p; non-small cell lung cancer; NSCLC, invasion; proliferation | ||
Published online: 24-Sep-2018 | ||
Year: 2018, Volume: 65, Issue: 5 | Page From: 673, Page To: 682 | |
doi:10.4149/neo_2018_170516N355 |
||
|
download file |
|